PolyPid Ltd. (PYPD): Price and Financial Metrics

PolyPid Ltd. (PYPD): $5.04

0.26 (-4.91%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add PYPD to Watchlist
Sign Up

PYPD Price/Volume Stats

Current price $5.04 52-week high $41.40
Prev. close $5.30 52-week low $4.62
Day low $4.62 Volume 3,390
Day high $5.04 Avg. volume 7,445
50-day MA $9.25 Dividend yield N/A
200-day MA $14.89 Market Cap 3.28M

PYPD Stock Price Chart Interactive Chart >


PolyPid Ltd. (PYPD) Company Bio


PolyPid Ltd. is a clinical stage biopharmaceutical company focusing on the development, manufacture, and commercialization of administered therapies to improve surgical outcomes. The company was founded by Noam Emanuel in 2008 and is headquartered in Petach Tikva, Israel.


PYPD Latest News Stream


Event/Time News Detail
Loading, please wait...

PYPD Latest Social Stream


Loading social stream, please wait...

View Full PYPD Social Stream

Latest PYPD News From Around the Web

Below are the latest news stories about POLYPID LTD that investors may wish to consider to help them evaluate PYPD as an investment opportunity.

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company’s management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York. Cantor Global Healthcare Conference: Presentation Date: Thursday, September 28, 2023Presentation Time:8:00 AM Eastern Time The PolyPid management team

Yahoo | September 22, 2023

PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health

Successful Audit of the Company’s State-of-the-Art Manufacturing Facility Represents a Key Milestone Toward Plan to Commercialize D-PLEX₁₀₀ GloballyPETACH TIKVA, Israel, Sept. 21, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Israeli Ministry of Health has completed a successful Good Manufacturing Practice (GMP) audit of the Company's manufacturing facility without an

Yahoo | September 21, 2023

PolyPid Announces Reverse Share Split

PETACH TIKVA, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders’ approval f

Yahoo | September 20, 2023

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA Regulatory Filings PETACH TIKVA, Israel, Sept. 19, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the successful completion of the production of three process validation batches of D-

Yahoo | September 19, 2023

PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage bio

Yahoo | August 9, 2023

Read More 'PYPD' Stories Here

PYPD Price Returns

1-mo -40.11%
3-mo -53.46%
6-mo -63.48%
1-year -84.59%
3-year -98.67%
5-year N/A
YTD -75.91%
2022 -87.85%
2021 -42.02%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!